10 January 2023
 |
ASCIA meetings in 2023
On behalf of the ASCIA team, best wishes for the new year.
We look forward to seeing you at ASCIA meetings this year, including the ASCIA 2023 Conference in September, and other meetings in March and May 2023, which are listed on the ASCIA Conference Meetings and Events Calendar
|
| |
|
 |
New ASCIA tick and mammalian meat allergy FAQ
A new FAQ about tick and mammalian meat allergy has been developed by ASCIA.
Clinical immunology/allergy specialists in Australia were the first to describe a link between tick bites and the development of mammalian meat allergy (MMA). In people with MMA, an allergic reaction can be caused by eating meat from mammals, meat products and animal-derived gelatin, which can be in food products and medications.
|
| |
|
 |
Updated ASCIA adrenaline injectors FAQ and other resources
ASCIA adrenaline injectors FAQ has been updated in 2023 to provide more clarity about using different doses and brands.
This FAQ is one of 11 ASCIA resources that have also been updated to include the Pharmac funding of EpiPen adrenaline injectors from February 2023. This will benefit thousands of New Zealanders with severe allergies who are at risk of anaphylaxis. Read more here
|
| |
|
 |
New primary immunodeficiency animation videos
Links to new animation videos about primary immunodeficiencies are now on the ASCIA website
These videos have been developed by the International Patient Organisation for Primary Immunodeficiencies (IPOPI), to increase the understanding of these conditions, the importance of early detection and access to treatments.
|
| |
|
 |
PBAC feedback due by 25 January 2023
The March 2023 meeting of the Pharmaceutical Benefits Advisory Committee (PBAC) includes three products that are relevant to ASCIA members - Jorveza® for EoE, EleCare® LCP for CMA and Saphnelo® for SLE. Feedback is due by 25 January 2023.
Read more here
|
| |
|
 |
How is ASCIA website information developed and updated?
There are more than 400 accessible, consistent and evidence-based resources on the ASCIA website, which are regularly developed, reviewed and updated. Updates are made in response to requests, recommendations, changes in clinical and academic expert consensus, changes in the published literature and product updates.
Read more here
|
| |
|
 |
Recent ASCIA website updates
Animation videos on ASCIA website
Voluntary recall of ALK peanut SPT batches
Allergic reactions to dental products containing Recaldent
ASCIA dietary guides updated with ReadSpeaker
New ASCIA HAE e-training for health professionals
Updated ASCIA HAE position paper
Updated ASCIA anaphylaxis e-training and action plans
New ASCIA anaphylaxis translations webpage
|
| |
|
 |
Current and future priorities for ASCIA
ASCIA priorities for 2022-2023 are listed on the ASCIA website
Thank you to all ASCIA members in Australia and New Zealand who completed a short survey, which will help to determine the most important current and future priorities for ASCIA. The survey is still open until the end of January and a report will be available by March.
|
| |
|
 |
ASCIA webpages listed below are regularly updated
ASCIA Submissions
ASCIA Collaborations
Publications
Research Studies
Locate a Specialist
Allergy/Immunology Positions
Conference, Meetings and Events Calendar
|
A gratefully acknowledges the generous support of all sponsors listed on the ASCIA website www.allergy.org.au/about-ascia/sponsors
www.allergy.org.au | contact us
The purpose of ASCIA is to advance the science and practice of allergy and clinical immunology, by promoting the highest standard of medical practice, training, education and research, to improve the health and quality of life of people with allergic diseases, immunodeficiencies and other immune diseases.
AIFA is dedicated to improving the health of people with allergy and other immune diseases by funding medical research and raising awareness. 